EGFR and lung carcinoma: Additionally, in some cases with limited available information on baseline biomarkers in tissue, Follow it® identified mutations that may interfere with the therapy chosen based on tissue testing alone, such as EGFR ctDNA mutations in lung cancer patients with PD-L1 expression.